Acta Crystallogr E Crystallogr Commun
October 2024
The mercury(II) halide complex [1,3-di--butyl-2,4-bis-(-butyl-amino)-1,3,2λ,4λ-di-aza-diphosphetidine-2,4-diselone-κ ,']di-iodido-mercury(II),-di-methyl-formamide monosolvate, [HgI(CHNPSe)]·CHNO or ()HgI, , containing -[( BuNH)(Se)P(μ-N Bu)P(Se)(NH Bu)] () was synthesized and structurally characterized. The crystal structure of confirms the chelation of chalcogen donors to HgI with a natural bite angle of 112.95 (2)°.
View Article and Find Full Text PDFPurpose: To compare the rate of re-detachment in patients with rhegmatogenous retinal detachment and Grade-C PVR following vitreoretinal surgery, with and without serial intravitreal injections of methotrexate.
Methods: It was a randomized control trial. Patients aged more than 18 years undergoing pars plana vitrectomy for rhegmatogenous retinal detachment with PVR grade C or more were included in the study.
Parkinson's disease, a neurodegenerative disorder, is quickly progressing and accounts for 15% of dementia cases. Parkinson's disease is the second most frequent form of neuronal degeneration after Alzheimer's, with an average age of 55 years for individuals exhibiting neuropsychiatric and physiological symptoms. Due to the effectiveness, low toxicity, and low side effects, bioactive compounds from plants have received increased attention recently as therapeutic drugs.
View Article and Find Full Text PDFThe title compound, [Ag(CHN)]Cl·0.5CHCl, can be readily generated by treatment of (1-benzyl-3-(2,4,6-tri-methyl-phen-yl)imidazolium chloride with sodium bis-(tri-methyl-sil-yl)amide followed by silver chloride. The mol-ecular structure of the compound was confirmed using NMR spectroscopy and single-crystal X-ray diffraction analysis.
View Article and Find Full Text PDF